Original Article
Cumulative Association of Five Genetic Variants with Prostate Cancer
N Engl J Med 2008; 358:910-919February 28, 2008
- Abstract
Background
Single-nucleotide polymorphisms (SNPs) in five chromosomal regions — three at 8q24 and one each at 17q12 and 17q24.3 — have been associated with prostate cancer. Each SNP has only a moderate association, but when SNPs are combined, the association may be stronger.
Methods
We evaluated 16 SNPs from five chromosomal regions in a Swedish population (2893 subjects with prostate cancer and 1781 control subjects) and assessed the individual and combined association of the SNPs with prostate cancer.
Results
Multiple SNPs in each of the five regions were associated with prostate cancer in single SNP analysis. When the most significant SNP from each of the five regions was selected and included in a multivariate analysis, each SNP remained significant after adjustment for other SNPs and family history. Together, the five SNPs and family history were estimated to account for 46% of the cases of prostate cancer in the Swedish men we studied. The five SNPs plus family history had a cumulative association with prostate cancer (P for trend, 3.93×10−28). In men who had any five or more of these factors associated with prostate cancer, the odds ratio for prostate cancer was 9.46 (P=1.29×10−8), as compared with men without any of the factors. The cumulative effect of these variants and family history was independent of serum levels of prostate-specific antigen at diagnosis.
Conclusions
SNPs in five chromosomal regions plus a family history of prostate cancer have a cumulative and significant association with prostate cancer.
Media in This Article
Table 1
Clinical and Demographic Characteristics of the Subjects.Article Activity
- Article
Genomewide association studies of complex diseases have identified sequence variants that are consistently associated with the risk of such diseases.1 Often such variants have limited use in the assessment of disease risk in an individual patient, since most of them confer a relatively small risk. Whether combinations of individual variants confer larger, more clinically useful associations with increased risk remains to be shown.
Age, race, and family history are three factors that have a consistent association with the risk of prostate cancer.2 A meta-analysis showed a pooled odds ratio of 2.5 for men who had a first-degree relative with the disease.3 Recently, genomewide analysis has identified variants in five chromosomal regions that are significantly associated with a risk of prostate cancer. These variants occur in three independent regions at 8q244-7 and in one region at 17q12 and another at 17q24.3.8 These five regions probably harbor genes that confer susceptibility to prostate cancer or regulate factors affecting critical genes, but the specific genes in these regions have not been identified.
Individually, single-nucleotide polymorphisms (SNPs) in each of the five chromosomal regions were shown to have only a moderate association with prostate cancer in previous studies. In our study, we investigated whether a combination of SNPs would have a stronger association with prostate cancer than any individual SNP. For this purpose, we assessed the joint associations of SNPs in the five chromosomal regions with prostate cancer in a large-scale study of Swedish men.
Methods
Study Subjects
The study population has been described in detail elsewhere.9 Briefly, we conducted a population-based, case–control study in Sweden, called CAPS (Cancer Prostate in Sweden). Subjects with prostate cancer were identified and recruited from four of the six regional cancer registries in Sweden. The inclusion criterion for case subjects was biopsy-confirmed or cytologically verified adenocarcinoma of the prostate, diagnosed between July 2001 and October 2003. Among 3648 identified subjects with prostate cancer, 3161 (87%) agreed to participate. DNA samples from blood, tumor–node–metastasis (TNM) stage, Gleason grade (as determined by biopsy), and levels of prostate-specific antigen (PSA) at diagnosis were available for 2893 subjects (92%). Case subjects were classified as having advanced disease if they met any of the following criteria: a grade 3 or 4 tumor, spread to nearby lymph nodes and metastasis, a Gleason score of 8 or more, or a PSA level of more than 50 ng per milliliter; otherwise, subjects were classified as having localized disease.
Control subjects, who were recruited concurrently with case subjects, were randomly selected from the Swedish Population Registry and matched according to the expected age distribution of cases (groups of 5-year intervals) and geographic region. A total of 2149 of 3153 control subjects (68%) who were invited subsequently agreed to participate in the study. DNA samples from blood were available for 1781 control subjects (83%). Serum PSA levels were measured for all control subjects but were not used as an exclusionary variable. A history of prostate cancer among first-degree relatives was obtained from a questionnaire for both case subjects and control subjects.
Table 1Table 1
Clinical and Demographic Characteristics of the Subjects. presents the demographic and clinical characteristics of the study subjects. Recruitment of the study population was completed in two phases, each with a similar number of subjects; the first phase (CAPS-1) ended October 31, 2002, and the second phase (CAPS-2) ended November 1, 2002. Each subject provided written informed consent. The study received institutional approval from the Karolinska Institutet, Umeå University, and Wake Forest University School of Medicine.Selection of SNPs for Genotyping
We selected 16 SNPs from five chromosomal regions (three at 8q24 and one each at 17q12 and 17q24.3) that have been reported to be associated with prostate cancer.6-8,10 Polymerase-chain-reaction (PCR) assays and extension primers for these SNPs were designed with the use of MassARRAY software, version 3.0 (Sequenom). (The primer information is available at www.wfubmc.edu/genomics.) PCR and extension reactions were performed according to the manufacturer's instructions, and extension product sizes were determined by mass spectrometry with the use of the iPLEX system (Sequenom). Duplicate test samples and two water samples (PCR-negative controls), of which the technician was unaware, were included in each 96-well plate. The rate of concordant results between duplicate samples was more than 99%.
Statistical Analysis
Tests for Hardy–Weinberg equilibrium were performed for each SNP separately among case subjects and control subjects with the use of Fisher's exact test. Pairwise linkage disequilibrium was tested for SNPs within each of the five chromosomal regions in control subjects with the use of SAS/Genetics software, version 9.0 (SAS Institute).
Differences in allele frequencies between case subjects and control subjects were tested for each SNP with the use of a chi-square test with 1 degree of freedom. Allelic odds ratios and 95% confidence intervals were estimated on the basis of a multiplicative model. For genotypes, a series of tests assuming an additive, dominant, or recessive genetic model were performed for each of the five SNPs with the use of unconditional logistic regression with adjustment for age and geographic region; the model that had the highest likelihood was considered to be the best-fitting genetic model for the respective SNP.
We tested the independent effect of each of the five previously implicated regions by including the most significant SNP from each of the five regions in a logistic-regression model with the use of a backward-selection procedure. Multiplicative interactions were tested for each pair of SNPs by including both main effects and an interaction term (a product of two main effects) in a logistic-regression model. We tested the cumulative effects of the five SNPs on prostate cancer by counting the number of genotypes associated with prostate cancer (on the basis of the best-fitting genetic model from single-SNP analysis) for these five SNPs in each subject. The odds ratio for prostate cancer for men carrying any combination of one, two, three, or four or more genotypes associated with prostate cancer was estimated by comparing them with men carrying none of the prostate-cancer–associated genotypes with the use of logistic-regression analysis. We also performed tests for the cumulative effect on prostate-cancer association, which included five SNPs and family history.
Population attributable risk (PAR) was estimated for SNPs that remained significant after adjustment for other covariates with the use of the following equation:
PAR% = 100×p(odds ratio−1) ÷ [p(odds ratio−1)+1].
In this equation, p is the prevalence of genotypes associated with prostate cancer among control subjects.11 The joint PAR was calculated on the basis of the individual PAR of each associated SNP, assuming no multiplicative interaction among the SNPs, with the use of the following equation
:In this equation, PARi is the individual PAR for each associated SNP calculated under the full model. For the model that included five SNPs and a family history of prostate cancer, the joint PAR for the associated factors was calculated in a similar manner.
Associations of these five SNPs with TNM stages, aggressiveness of prostate cancer (advanced or localized), and family history (yes or no) were tested only among case subjects with the use of a chi-square test of a 2×K table, in which K is the number of possible categories within each variable. A test for trend was used to assess the proportion of genotypes associated with prostate cancer with each increasing Gleason score, from 4 or less to 10. Associations of SNPs with the mean age at diagnosis were tested only among case subjects with the use of a two-sample t-test. Because serum PSA levels were not normally distributed, a nonparametric analysis (Wilcoxon rank-sum test) was used to assess the association between SNPs and preoperative serum PSA levels in case subjects or PSA levels at the time of sampling in control subjects. All reported P values are based on a two-sided test.
Results
Sixteen SNPs in five chromosomal regions (three at 8q24 and two at 17q), which were previously implicated in harboring genes that confer susceptibility to prostate cancer, were evaluated. In the control group, each SNP was in Hardy–Weinberg equilibrium (P≥0.05). Significant pairwise linkage disequilibrium (P<0.05) was observed for the SNPs within each region.
Table 2Table 2
Association of SNPs at Five Chromosomal Regions with Prostate Cancer. lists allele frequencies of the 16 SNPs among case and control subjects and shows the results of allelic and genotypic tests. Significantly different frequencies (P<0.05) between case and control subjects were observed for SNPs in each of the five chromosomal regions. At 17q12, SNP rs4430796 had the strongest association with prostate cancer; the frequency of allele T (SNP rs4430796) was 0.61 in case subjects and 0.56 in control subjects (P=6.0×10−7). Of the four SNPs at 17q24.3, three were associated with prostate cancer, but only rs1859962 had a highly significant association (P=2.1×10−4). The results for 17q12 and 17q24.3 were similar to those that were reported previously.8 For SNPs at 8q24, significant associations with prostate cancer were found for all SNPs examined across the three independent regions at 8q24. Of the 16 SNPs, 13 remained significant at P<0.05 after adjustment for 16 tests with the use of a Bonferroni correction.Carriers of previously reported risk-associated alleles for SNPs at 17q12, 17q24.3, and 8q24 were significantly more likely to have prostate cancer than were control subjects (Table 2). When various genetic models were tested for SNPs at each region, a recessive model was the best-fitting genetic model for SNPs at 17q12 and 17q24.3, and a dominant model was the best-fitting genetic model for SNPs at regions 1, 2, and 3 of 8q24.
Strong genetic dependence (linkage disequilibrium) among SNPs within each region allowed for a combined analysis in which we were able to select one SNP (the most significant SNP from single SNP analysis) to represent each of the five regions in tests for an independent association with prostate cancer (Table 3Table 3
Adjusted Odds Ratios and Population Attributable Risks (PARs) for Representative SNPs at Five Chromosomal Regions and Family History.). When these five SNPs were included in a multivariate logistic-regression model, each of the five remained significantly associated with prostate cancer after adjustment for other SNPs, and each continued to be highly significant when family history was included in the model. On the basis of adjusted odds ratios for each of these five SNPs and a positive family history, PARs were estimated to account for 4 to 21% of prostate-cancer cases in the Swedish population we studied. The estimated joint PAR for prostate cancer of the five associated SNPs plus family history was 46% in the studied population.When multiplicative interaction was tested for each possible pair of these five SNPs with the use of an interaction term in logistic regression, none were significant at P<0.05. However, the five SNPs appeared to have a cumulative association with prostate cancer, after adjustment for age, geographic region, and family history (Table 4Table 4
Cumulative Effect of Associated Factors on the Risk of Prostate Cancer.). Men who carried one, two, three, or four or more of the five SNPs had an increasing likelihood of having prostate cancer, as compared with men who did not carry any of the five SNPs (P for trend, 6.75×10−27). When family history was included as another risk factor (coded as 0 or 1) for a total of six possible prostate-cancer associated factors, we observed a stronger cumulative effect after adjustment for age and geographic region (P for trend, 4.78×10−28). For example, men who carried any five or more of these six factors had an odds ratio of 9.46 (95% confidence interval [CI], 3.62 to 24.72) for prostate cancer, as compared with men who carried none of the six factors (P=1.29×10−8). This cumulative effect was similarly observed in two subgroups of study subjects, with a P for trend of 1.36×10−10 in CAPS-1 and of 9.03×10−20 in CAPS-2 (data not shown).We calculated the specificity and sensitivity of the regression model by constructing receiver-operating-characteristic (ROC) curves and calculated statistics for the area under the curve (AUC) to estimate the ability of each of three models to distinguish case subjects from control subjects. The AUC was 57.7 (95% CI, 56.0 to 59.3) for model 1 (age and region alone), 60.8 (95% CI, 59.1 to 62.4) for model 2 (age, region, and family history), and 63.3 (95% CI, 61.7 to 65.0) for model 3 (age, region, family history, and the number of genotypes associated with prostate cancer at the five SNPs). The AUC was significantly higher for model 3 than for model 2 (P=6.12×10−6). It is important to note that overfitting could have influenced our results, and for this reason the models require verification in independent populations.
Table 5Table 5
Association of Five SNPs with Clinical Characteristics. shows that none of the five SNPs were significantly associated with the aggressiveness of prostate cancer, the Gleason score, the presence or absence of family history, the serum PSA level at diagnosis, or the age at diagnosis. Furthermore, no associations with these clinical variables were found when multiple SNPs associated with prostate cancer were considered simultaneously. For example, the 154 case subjects who carried four or more of the five SNPs were not significantly different from the 162 case subjects who had none of the SNPs with regard to the following clinical variables: positive family history (17% with four or more SNPs and 21% with no SNPs, P=0.39), the proportion with advanced disease (54% and 48%, respectively; P=0.33), and the median serum PSA level at diagnosis (15 ng and 14 ng per milliliter, respectively; P=0.27). A lack of association between the SNPs at 8q24 and clinical characteristics was also reported previously,7,12-14 but in other studies a trend was found between 8q24 SNPs and a high Gleason grade, tumor stage, and aggressive disease.4-6,15,16 Thus, the association of these SNPs with clinical features of prostate cancer remains an open question.Discussion
In genomewide studies, multiple chromosomal regions at 8q24 and 17q have been associated with prostate cancer.4-8 All three regions at 8q24 have been replicated in all published studies,10,12-16 but no study has yet replicated the associations in regions at 17q. The highly significant findings at 17q12 and 17q24.3 in our study independently confirm the association of these two regions with prostate cancer. In addition, we confirmed the association of SNPs at regions 1, 2, and 3 of 8q24 with prostate cancer. This independent confirmation of the association of these five chromosomal regions with prostate cancer supports the validity of genetic association studies in complex diseases.
Although each of the SNPs in the five chromosomal regions was only moderately associated with prostate cancer, we found that they had a strong cumulative association with the disease. We estimated that men who have five or more of the six factors associated with prostate cancer (specific genotypes at five SNPs and a positive family history for the disease) have an odds ratio of 9.46 for prostate cancer. The cumulative effect is highly significant in our overall study sample (P for trend, 4.78×10−28) and consistent between the two subgroups in CAPS-1 and CAPS-2. It may be possible to use the combined information from the five SNPs and family history to assess an individual patient's risk of prostate cancer, but this strategy will have to be tested in a prospective study before proceeding with any such risk assessments.
We found that the presence of the five prostate-cancer–associated SNPs was independent of PSA levels in both case subjects (Table 5) and control subjects (data not shown), which suggests that some men with low PSA levels may have an increased risk of prostate cancer if they carry one or more of the prostate-cancer–associated genotypes described here. However, this proposition also requires testing in a prospective trial, particularly one that uses PSA in combination with the associated SNPs and family history.
We do not know the mechanism by which the SNPs we analyzed could affect the risk of prostate cancer. Other than SNP rs4430796, which is located within the TCF2 gene, the specific genes that are affected by the rest of the SNPs have not been identified. Since the five SNPs in our study appear to be associated with a risk of prostate cancer in general, rather than with a more or less aggressive form, we suspect that the genetic variants act at an early stage of carcinogenesis.
Our study is only a first step toward defining a genetic association with prostate cancer in populations. Future investigations will need to test the value of these findings in assessing the risk of prostate cancer in individual men.
Supported by grants (CA105055, CA106523, and CA95052, to Dr. Xu, and CA112517 and CA58236, to Dr. Isaacs) from the National Cancer Institute; a grant (PC051264, to Dr. Xu) from the Department of Defense; grants (to Dr. Grönberg) from the Swedish Cancer Society and the Swedish Academy of Sciences; an endowment from William T. Gerrard, Mario A. Duhon, and John and Jennifer Chalsty (to Dr. Isaacs); and a David H. Koch award (to Dr. Isaacs) from the Prostate Cancer Foundation.
A patent application has been filed by the Wake Forest University School of Medicine, Johns Hopkins University School of Medicine, and Dr. Henrik Grönberg at Karolinska Institutet, Stockholm, to preserve patent rights for the technology and results described in this study. No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa075819) was published at www.nejm.org on January 16, 2008.
We thank all the study subjects who participated in the CAPS study and urologists who included their patients in the CAPS study, the Regional Cancer Registries, and the CAPS steering committee, including Drs. Jan Adolfsson, Jan-Erik Johansson, and Eberhart Varenhorst.
Source Information
From the Center for Human Genomics (S.L.Z., J.S., S.S., G.L., F.-C.H., Y.Z., A.R.T., W.L., E.R.B., D.A.M., B.-L.C., J.X.) and the Departments of Biostatistical Sciences (F.-C.H.) and Urology (A.K.K.), Wake Forest University School of Medicine, Winston-Salem, NC; the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (F.W., H.-O.A., K.B., H.G.); the Department of Urology, Umeå University Hospital, Umeå, Sweden (P.S.); the Department of Epidemiology, Harvard School of Public Health, Boston (H.-O.A.); Translational Genomics Research Institute, Phoenix, AZ (D.D., J.D.C.); and Johns Hopkins Medical Institutions, Baltimore (W.B.I.).
Address reprint requests to Dr. Xu at the Center for Human Genomics, Medical Center Blvd., Winston-Salem, NC 27157, or at jxu@wfubmc.edu; or to Dr. Isaacs at Marburg 115, Johns Hopkins Hospital, 600 N. Wolfe St., Baltimore, MD 21287, or at wisaacs@jhmi.edu.
- References
References
1
Hunter DJ ,Kraft P . Drinking from the fire hose -- statistical issues in genomewide association studies. N Engl J Med 2007;357:436-439
Full Text | Web of Science | Medline2
Gronberg H . Prostate cancer epidemiology. Lancet 2003;361:859-864
CrossRef | Web of Science | Medline3
Johns LE ,Houlston RS . A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003;91:789-794
CrossRef | Web of Science | Medline4
Amundadottir LT ,Sulem P ,Gudmundsson J , et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006;38:652-658
CrossRef | Web of Science | Medline5
Gudmundsson J ,Sulem P ,Manolescu A , et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007;39:631-637
CrossRef | Web of Science | Medline6
Haiman CA ,Patterson N ,Freedman ML , et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007;39:638-644
CrossRef | Web of Science | Medline7
Yeager M ,Orr N ,Hayes RB , et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39:645-649
CrossRef | Web of Science | Medline8
Gudmundsson J ,Sulem P ,Steinthorsdottir V , et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007;39:977-983
CrossRef | Web of Science | Medline9
Lindstrom S ,Wiklund F ,Adami HO ,Balter KA ,Adolfsson J ,Gronberg H . Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development. Cancer Res 2006;66:11077-11083
CrossRef | Web of Science | Medline10
Zheng SL ,Sun J ,Cheng Y , et al. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst 2007;99:1525-1533
CrossRef | Web of Science | Medline11
Linkage disequilibrium. In: Lilienfeld AM, Lilienfeld DE. Foundations of epidemiology. 2nd ed. New York: Oxford University Press, 1980:301-11.
12
Freedman ML ,Haiman CA ,Patterson N , et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 2006;103:14068-14073
CrossRef | Web of Science | Medline13
Severi G ,Hayes VM ,Padilla EJ , et al. The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007;16:610-612
CrossRef | Web of Science | Medline14
Schumacher FR ,Feigelson HS ,Cox DG , et al. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res 2007;67:2951-2956
CrossRef | Web of Science | Medline15
Wang L ,McDonnell SK ,Slusser JP , et al. Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res 2007;67:2944-2950
CrossRef | Web of Science | Medline16
Suuriniemi M ,Agalliu I ,Schaid DJ , et al. Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biomarkers Prev 2007;16:809-814
CrossRef | Web of Science | Medline
- Citing Articles (162)
Citing Articles
1
Christopher E Barbieri, Francesca Demichelis, Mark A Rubin. (2012) Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology 60:1, 187-198
CrossRef2
Mattias Johansson, Benny Holmström, Sally R. Hinchliffe, Anders Bergh, Ulf-Håkan Stenman, Göran Hallmans, Fredrik Wiklund, Pär Stattin. (2012) Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: Longitudinal study. International Journal of Cancer 130:1, 129-137
CrossRef3
Adam B. Murphy, Flora Ukoli, Vincent Freeman, Frankly Bennett, William Aiken, Trevor Tulloch, Kathleen Coard, Fru Angwafo, Rick A. Kittles. (2012) 8q24 risk alleles in West African and Caribbean men. The Prostaten/a-n/a
CrossRef4
E L Ivansson, I Juko-Pecirep, H A Erlich, U B Gyllensten. (2011) Pathway-based analysis of genetic susceptibility to cervical cancer in situ: HLA-DPB1 affects risk in Swedish women. Genes and Immunity 12:8, 605-614
CrossRef5
Chun Wang, Ying Li, Jianling Bai, Weichong Qian, Jian Zhou, Zhiming Sun, Lei Ba, Wei Wei, Huiqiao Li, Tao Sun. (2011) General and Central Obesity, Combined Oral Contraceptive Use and Hypertension in Chinese Women. American Journal of Hypertension 24:12, 1324-1330
CrossRef6
Barry B. McGuire, Brian T. Helfand, Shilajit Kundu, Qiaoyan Hu, Jessica A. Banks, Phillip Cooper, William J. Catalona. (2011) Association of prostate cancer risk alleles with unfavourable pathological characteristics in potential candidates for active surveillance. BJU Internationalno-no
CrossRef7
Hidewaki Nakagawa, Shusuke Akamatsu, Ryo Takata, Atsushi Takahashi, Michiaki Kubo, Yusuke Nakamura. (2011) Prostate Cancer Genomics, Biology, and Risk Assessment through Genome-wide Association Studies. Cancer Scienceno-no
CrossRef8
Andrew J. Vickers, Hans Lilja. (2011) Predicting prostate cancer many years before diagnosis: how and why?. World Journal of Urology
CrossRef9
Cheryl D. Cropp, Claire L Simpson, Tiina Wahlfors, Nati Ha, Asha George, MaryPat S. Jones, Ursula Harper, Damaris Ponciano-Jackson, Tiffany A. Green, Teuvo L. J. Tammela, Joan Bailey-Wilson, Johanna Schleutker. (2011) Genome-wide linkage scan for prostate cancer susceptibility in Finland: Evidence for a novel locus on 2q37.3 and confirmation of signal on 17q21-q22. International Journal of Cancer 129:10, 2400-2407
CrossRef10
Amalia Papanikolopoulou, Olfert Landt, Konstantinos Ntoumas, Stefanos Bolomitis, Stavros I. Tyritzis, Constantinos Constantinides, Nikolaos Drakoulis. (2011) The multi-cancer marker, rs6983267, located at region 3 of chromosome 8q24, is associated with prostate cancer in Greek patients but does not contribute to the aggressiveness of the disease. Clinical Chemistry and Laboratory Medicine---
CrossRef11
Jane Bayani, Eleftherios P. Diamandis. (2011) Review: The physiology and pathobiology of human kallikrein-related peptidase 6 ( KLK6 ). Clinical Chemistry and Laboratory Medicine---
CrossRef12
Thomas J. Walsh. (2011) Male reproductive health and prostate cancer risk. Current Opinion in Urology 21:6, 506-513
CrossRef13
Robert J. Klein, Christer Hallden, Amit Gupta, Caroline J. Savage, Anders Dahlin, Anders Bjartell, Jonas Manjer, Peter T. Scardino, David Ulmert, Peter Wallström, Andrew J. Vickers, Hans Lilja. (2011) Evaluation of Multiple Risk–Associated Single Nucleotide Polymorphisms Versus Prostate-Specific Antigen at Baseline to Predict Prostate Cancer in Unscreened Men. European Urology
CrossRef14
Phillip R. Cooper, Barry B. McGuire, Brian T. Helfand, Stacy Loeb, Qiaoyan Hu, William J. Catalona. (2011) Prostate Cancer Risk Alleles and Their Associations With Other Malignancies. Urology 78:4, 970.e15-970.e20
CrossRef15
David W. Craig, Robert M. Goor, Zhenyuan Wang, Justin Paschall, Jim Ostell, Michael Feolo, Stephen T. Sherry, Teri A. Manolio. (2011) Assessing and managing risk when sharing aggregate genetic variant data. Nature Reviews Genetics 12:10, 730-736
CrossRef16
Amanda K. Miles, Alistair Rogers, Thomas McCulloch, Zsolt Hodi, Stephanie McArdle, Michael Bishop, Robert C. Rees. (2011) Expression of the tumour antigen T21 is up-regulated in prostate cancer and is associated with tumour stage. BJU Internationalno-no
CrossRef17
A. Cecile. J. W. Janssens, John P. A. Ioannidis, Sara Bedrosian, Paolo Boffetta, Siobhan M. Dolan, Nicole Dowling, Isabel Fortier, Andrew N. Freedman, Jeremy M. Grimshaw, Jeffrey Gulcher, Marta Gwinn, Mark A. Hlatky, Holly Janes, Peter Kraft, Stephanie Melillo, Christopher J. O’Donnell, Michael J. Pencina, David Ransohoff, Sheri D. Schully, Daniela Seminara, Deborah M. Winn, Caroline F. Wright, Cornelia M. van Duijn, Julian Little, Muin J. Khoury. (2011) Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Clinical Investigation 41:9, 1010-1035
CrossRef18
Motofumi Suzuki, Miao Liu, Takayuki Kurosaki, Makoto Suzuki, Tomio Arai, Motoji Sawabe, Yutaka Kasuya, Moriaki Kato, Tetsuya Fujimura, Hiroshi Fukuhara, Yutaka Enomoto, Hiroaki Nishimatsu, Akira Ishikawa, Haruki Kume, Yukio Homma, Tadaichi Kitamura. (2011) Association of rs6983561 Polymorphism at 8q24 With Prostate Cancer Mortality in a Japanese Population. Clinical Genitourinary Cancer 9:1, 46-52
CrossRef19
A. Cecile J.W. Janssens, John P.A. Ioannidis, Sara Bedrosian, Paolo Boffetta, Siobhan M. Dolan, Nicole Dowling, Isabel Fortier, Andrew N. Freedman, Jeremy M. Grimshaw, Jeffrey Gulcher, Marta Gwinn, Mark A. Hlatky, Holly Janes, Peter Kraft, Stephanie Melillo, Christopher J. O’Donnell, Michael J. Pencina, David Ransohoff, Sheri D. Schully, Daniela Seminara, Deborah M. Winn, Caroline F. Wright, Cornelia M. van Duijn, Julian Little, Muin J. Khoury. (2011) Strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS): explanation and elaboration. Journal of Clinical Epidemiology 64:8, e1-e22
CrossRef20
T. A. Wallace, D. N. Martin, S. Ambs. (2011) Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis 32:8, 1107-1121
CrossRef21
Charles C. Chung, Stephen J. Chanock. (2011) Current status of genome-wide association studies in cancer. Human Genetics 130:1, 59-78
CrossRef22
Minori Koga, Aya Kawasaki, Ikue Ito, Takumi Furuya, Jun Ohashi, Chieko Kyogoku, Satoshi Ito, Taichi Hayashi, Isao Matsumoto, Makio Kusaoi, Yoshinari Takasaki, Hiroshi Hashimoto, Takayuki Sumida, Naoyuki Tsuchiya. (2011) Cumulative association of eight susceptibility genes with systemic lupus erythematosus in a Japanese female population. Journal of Human Genetics 56:7, 503-507
CrossRef23
Ke-Da Yu, Qi Fang, Zhi-Ming Shao. (2011) Combining accurate genetic and clinical information in breast cancer risk model. Breast Cancer Research and Treatment 128:1, 283-285
CrossRef24
Miao Liu, Motofumi Suzuki, Tomio Arai, Motoji Sawabe, Yutaka Enomoto, Hiroaki Nishimatsu, Haruki Kume, Yukio Homma, Tadaichi Kitamura. (2011) A replication study examining three common single-nucleotide polymorphisms and the risk of prostate cancer in a Japanese population. The Prostate 71:10, 1023-1032
CrossRef25
Chunmei C Xie, Lingyi Lu, Jielin Sun, S Lilly Zheng, William B Isaacs, Henrik Gronberg, Jianfeng Xu. (2011) Germ-line sequence variants of PTEN do not have an important role in hereditary and non-hereditary prostate cancer susceptibility. Journal of Human Genetics 56:7, 496-502
CrossRef26
Nora Pashayan, Paul Pharoah. (2011) Translating genomics into improved population screening: hype or hope?. Human Genetics 130:1, 19-21
CrossRef27
A. Ghosh, P. E. Castle. (2011) Invited Commentary: The Importance of Prevalence in the Effectiveness of a (Bio)marker. American Journal of Epidemiology 173:12, 1388-1390
CrossRef28
Chen Wu, Zhibin Hu, Zhonghu He, Weihua Jia, Feng Wang, Yifeng Zhou, Zhihua Liu, Qimin Zhan, Yu Liu, Dianke Yu, Kan Zhai, Jiang Chang, Yan Qiao, Guangfu Jin, Zhe Liu, Yuanyuan Shen, Chuanhai Guo, Jianhua Fu, Xiaoping Miao, Wen Tan, Hongbing Shen, Yang Ke, Yixin Zeng, Tangchun Wu, Dongxin Lin. (2011) Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nature Genetics 43:7, 679-684
CrossRef29
Jae Young Joung, Yeon-Su Lee, Sohee Park, Hyekyoung Yoon, Sang Jin Lee, Weon Seo Park, Ho Kyung Seo, Jinsoo Chung, Sook-young Kim, Seung-Hyun Hong, Jeong Seon Kim, Kang Hyun Lee. (2011) Haplotype Analysis of Prostate Stem Cell Antigen and Association With Prostate Cancer Risk. The Journal of Urology 185:6, 2112-2118
CrossRef30
Zongli Xu, Jeannette T. Bensen, Gary J. Smith, James L. Mohler, Jack A. Taylor. (2011) GWAS SNP Replication among African American and European American men in the North Carolina-Louisiana prostate cancer project (PCaP). The Prostate 71:8, 881-891
CrossRef31
Markus Aly, Fredrik Wiklund, Henrik Grönberg. (2011) Early detection of prostate cancer with emphasis on genetic markers. Acta Oncologica 50:S1, 18-23
CrossRef32
Cheng-Hong Yang, Li-Yeh Chuang, Yu-Jung Chen, Hung-Fu Tseng, Hsueh-Wei Chang. (2011) Computational Analysis of Simulated SNP Interactions Between 26 Growth Factor-Related Genes in a Breast Cancer Association Study. OMICS: A Journal of Integrative Biology 15:6, 399-407
CrossRef33
X. Wu, Y. Ye, R. Rosell, C. I. Amos, D. J. Stewart, M. A. T. Hildebrandt, J. A. Roth, J. D. Minna, J. Gu, J. Lin, S. C. Buch, T. Nukui, J. L. Ramirez Serrano, M. Taron, A. Cassidy, C. Lu, J. Y. Chang, S. M. Lippman, W. K. Hong, M. R. Spitz, M. Romkes, P. Yang. (2011) Genome-Wide Association Study of Survival in Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy. JNCI Journal of the National Cancer Institute 103:10, 817-825
CrossRef34
N Pashayan, S W Duffy, S Chowdhury, T Dent, H Burton, D E Neal, D F Easton, R Eeles, P Pharoah. (2011) Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. British Journal of Cancer 104:10, 1656-1663
CrossRef35
A Cecile JW Janssens, John PA Ioannidis, Sara Bedrosian, Paolo Boffetta, Siobhan M Dolan, Nicole Dowling, Isabel Fortier, Andrew N Freedman, Jeremy M Grimshaw, Jeffrey Gulcher, Marta Gwinn, Mark A Hlatky, Holly Janes, Peter Kraft, Stephanie Melillo, Christopher J O'Donnell, Michael J Pencina, David Ransohoff, Sheri D Schully, Daniela Seminara, Deborah M Winn, Caroline F Wright, Cornelia M van Duijn, Julian Little, Muin J Khoury. (2011) Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Human Genetics 19:5,
CrossRef36
Wei Wang, Tianxin Lin, Jian Huang, Weilie Hu, Kewei Xu, Jun Liu. (2011) Analysis of Mel-18 expression in prostate cancer tissues and correlation with clinicopathologic features. Urologic Oncology: Seminars and Original Investigations 29:3, 244-251
CrossRef37
Federico Innocenti, Nancy J. Cox, M. Eileen Dolan. (2011) The Use of Genomic Information to Optimize Cancer Chemotherapy. Seminars in Oncology 38:2, 186-195
CrossRef38
A. Cecile J. W. Janssens, John P. A. Ioannidis, Sara Bedrosian, Paolo Boffetta, Siobhan M. Dolan, Nicole Dowling, Isabel Fortier, Andrew N. Freedman, Jeremy M. Grimshaw, Jeffrey Gulcher, Marta Gwinn, Mark A. Hlatky, Holly Janes, Peter Kraft, Stephanie Melillo, Christopher J. O’Donnell, Michael J. Pencina, David Ransohoff, Sheri D. Schully, Daniela Seminara, Deborah M. Winn, Caroline F. Wright, Cornelia M. Duijn, Julian Little, Muin J. Khoury. (2011) Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Epidemiology 26:4, 313-337
CrossRef39
Hans Lilja, Angel M. Cronin, Anders Dahlin, Jonas Manjer, Peter M. Nilsson, James A. Eastham, Anders S. Bjartell, Peter T. Scardino, David Ulmert, Andrew J. Vickers. (2011) Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 117:6, 1210-1219
CrossRef40
Jielin Sun, A. Karim Kader, Fang-Chi Hsu, Seong-Tae Kim, Yi Zhu, Aubrey R. Turner, Tao Jin, Zheng Zhang, Jan Adolfsson, Fredrik Wiklund, S. Lilly Zheng, William B. Isaacs, Henrik Grönberg, Jianfeng Xu. (2011) Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. The Prostate 71:4, 421-430
CrossRef41
Brian T. Helfand, Donghui Kan, Parth Modi, William J. Catalona. (2011) Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a “normal” prostate specific antigen and digital rectal examination. The Prostate 71:4, 394-402
CrossRef42
Shelby D. Reed, Charles D. Scales, Suzanne B. Stewart, Jielin Sun, Judd W. Moul, Kevin A. Schulman, Jianfeng Xu. (2011) Effects of Family History and Genetic Polymorphism on the Cost-Effectiveness of Chemoprevention With Finasteride for Prostate Cancer. The Journal of Urology 185:3, 841-847
CrossRef43
Catharine B Stack, Neda Gharani, Erynn S Gordon, Tara Schmidlen, Michael F Christman, Margaret A Keller. (2011) Genetic risk estimation in the Coriell Personalized Medicine Collaborative. Genetics in Medicine 13:2, 131-139
CrossRef44
Ramal Moonesinghe, Muin J Khoury, Tiebin Liu, A Cecile JW Janssens. (2011) Discriminative accuracy of genomic profiling comparing multiplicative and additive risk models. European Journal of Human Genetics 19:2, 180-185
CrossRef45
Veda N. Giri, Karen Ruth, Lucinda Hughes, Robert G. Uzzo, David Y.T. Chen, Stephen A. Boorjian, Rosalia Viterbo, Timothy R. Rebbeck. (2011) Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val. BJU International 107:3, 466-470
CrossRef46
Markus Aly, Fredrik Wiklund, Jianfeng Xu, William B. Isaacs, Martin Eklund, Mauro D’Amato, Jan Adolfsson, Henrik Grönberg. (2011) Polygenic Risk Score Improves Prostate Cancer Risk Prediction: Results from the Stockholm-1 Cohort Study. European Urology
CrossRef47
Mark M. Pomerantz, Matthew L. Freedman. (2011) The Genetics of Cancer Risk. The Cancer Journal 17:6, 416-422
CrossRef48
Robert J. MacInnis, Antonis C. Antoniou, Rosalind A. Eeles, Gianluca Severi, Ali Amin Al Olama, Lesley McGuffog, Zsofia Kote-Jarai, Michelle Guy, Lynne T. O'Brien, Amanda L. Hall, Rosemary A. Wilkinson, Emma Sawyer, Audrey T. Ardern-Jones, David P. Dearnaley, Alan Horwich, Vincent S. Khoo, Christopher C. Parker, Robert A. Huddart, Nicholas Van As, Margaret R. McCredie, Dallas R. English, Graham G. Giles, John L. Hopper, Douglas F. Easton. (2011) A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genetic Epidemiologyn/a-n/a
CrossRef49
Yash R. Patel, Katherine A. Carr, David Magjuka, Yousef Mohammadi, Edward F. Dropcho, Angela D. Reed, Marietta L. Moore, Mary Jane Waddell, Rivienne Shedd-Steele, Christopher J. Sweeney, Noah M. Hahn. (2011) Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs. Cancern/a-n/a
CrossRef50
Kristin M. Pearson-Fuhrhop, Steven C. Cramer. (2010) Genetic Influences on Neural Plasticity. PM&R 2:12, S227-S240
CrossRef51
Brian T. Helfand, Stacy Loeb, Donghui Kan, William J. Catalona. (2010) Number of prostate cancer risk alleles may identify possibly ‘insignificant’ disease. BJU International 106:11, 1602-1606
CrossRef52
Monica Leu, Keith Humphreys, Ida Surakka, Emil Rehnberg, Juha Muilu, Päivi Rosenström, Peter Almgren, Juha Jääskeläinen, Richard P Lifton, Kirsten Ohm Kyvik, Jaakko Kaprio, Nancy L Pedersen, Aarno Palotie, Per Hall, Henrik Grönberg, Leif Groop, Leena Peltonen, Juni Palmgren, Samuli Ripatti. (2010) NordicDB: a Nordic pool and portal for genome-wide control data. European Journal of Human Genetics 18:12, 1322-1326
CrossRef53
M. E. Mealiffe, R. P. Stokowski, B. K. Rhees, R. L. Prentice, M. Pettinger, D. A. Hinds. (2010) Assessment of Clinical Validity of a Breast Cancer Risk Model Combining Genetic and Clinical Information. JNCI Journal of the National Cancer Institute 102:21, 1618-1627
CrossRef54
Mark M. Pomerantz, Matthew L. Freedman. (2010) Genetics of Prostate Cancer Risk. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:6, 643-654
CrossRef55
Stacy Loeb, Gustavo F. Carvalhal, William J. Catalona. (2010) Reply. Urology 76:5, 1076-1077
CrossRef56
Charles Kooperberg, Michael LeBlanc, Valerie Obenchain. (2010) Risk prediction using genome-wide association studies. Genetic Epidemiology 34:7, 643-652
CrossRef57
M. Beekman, C. Nederstigt, H. E. D. Suchiman, D. Kremer, R. van der Breggen, N. Lakenberg, W. G. Alemayehu, A. J. M. de Craen, R. G. J. Westendorp, D. I. Boomsma, E. J. C. de Geus, J. J. Houwing-Duistermaat, B. T. Heijmans, P. E. Slagboom. (2010) Genome-wide association study (GWAS)-identified disease risk alleles do not compromise human longevity. Proceedings of the National Academy of Sciences 107:42, 18046-18049
CrossRef58
Zsofia K. Stadler, Joseph Vijai, Peter Thom, Tomas Kirchhoff, Nichole A.L. Hansen, Noah D. Kauff, Mark Robson, Kenneth Offit. (2010) Genome-wide Association Studies of Cancer Predisposition. Hematology/Oncology Clinics of North America 24:5, 973-996
CrossRef59
Jerome Carayol, Frédéric Tores, Inke R. König, Jörg Hager, Andreas Ziegler. (2010) Evaluating diagnostic accuracy of genetic profiles in affected offspring families. Statistics in Medicine 29:22, 2359-2368
CrossRef60
Graham H.M. Goddard, Cathryn M. Lewis. (2010) Risk categorization for complex disorders according to genotype relative risk and precision in parameter estimates. Genetic Epidemiology 34:6, 624-632
CrossRef61
Bo-Ying Bao, Jiunn-Bey Pao, Victor C. Lin, Chun-Nung Huang, Ta-Yuan Chang, Yu-Hsuan Lan, Te-Ling Lu, Hong-Zin Lee, Lu-Min Chen, Wen-Chien Ting, Chi-Jeng Hsieh, Shu-Pin Huang. (2010) Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease. Clinica Chimica Acta 411:17-18, 1232-1237
CrossRef62
Ryan M. Huebinger, Harold R. Garner, Robert C. Barber. (2010) Pathway genetic load allows simultaneous evaluation of multiple genetic associations. Burns 36:6, 787-792
CrossRef63
Seth A. Strope, Gerald L. Andriole. (2010) Prostate cancer screening: current status and future perspectives. Nature Reviews Urology 7:9, 487-493
CrossRef64
Deborah A. Meyers. (2010) Genetics of asthma and allergy: What have we learned?. Journal of Allergy and Clinical Immunology 126:3, 439-446
CrossRef65
H Chen, W Liu, W Roberts, S Hooker, H Fedor, A DeMarzo, W Isaacs, R A Kittles. (2010) 8q24 allelic imbalance and MYC gene copy number in primary prostate cancer. Prostate Cancer and Prostatic Diseases 13:3, 238-243
CrossRef66
Ching-Lung Cheung, Su-Mei Xiao, Annie W. C. Kung. (2010) Genetic epidemiology of age-related osteoporosis and its clinical applications. Nature Reviews Rheumatology 6:9, 507-517
CrossRef67
John W. Holloway, Syed H. Arshad, Stephen T. Holgate. (2010) Using genetics to predict the natural history of asthma?. Journal of Allergy and Clinical Immunology 126:2, 200-209
CrossRef68
Tatsuya Hamano, Hiroshi Matsui, Yoshitaka Sekine, Nobuaki Ohtake, Seiji Nakata, Kazuhiro Suzuki. (2010) Association of SNP rs1447295 and Microsatellite Marker DG8S737 With Familial Prostate Cancer and High Grade Disease. The Journal of Urology 184:2, 738-742
CrossRef69
Juan Morote, Jokin del Amo, Angel Borque, Elisabet Ars, Carlos Hernández, Felipe Herranz, Antonio Arruza, Roberto Llarena, Jacques Planas, María J. Viso, Joan Palou, Carles X. Raventós, Diego Tejedor, Marta Artieda, Laureano Simón, Antonio Martínez, Luis A. Rioja. (2010) Improved Prediction of Biochemical Recurrence After Radical Prostatectomy by Genetic Polymorphisms. The Journal of Urology 184:2, 506-511
CrossRef70
M. Chen, J. Gu, G. L. Delclos, A. M. Killary, Z. Fan, M. A. T. Hildebrandt, R. M. Chamberlain, H. B. Grossman, C. P. Dinney, X. Wu. (2010) Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis 31:8, 1387-1391
CrossRef71
A-Yong Cao, Ke-Da Yu, Wen-Jin Yin, Wei Jin, Gen-Hong Di, Zhen-Zhou Shen, Zhi-Ming Shao. (2010) Five common single nucleotide polymorphisms in the PALB2 gene and susceptibility to breast cancer in eastern Chinese population. Breast Cancer Research and Treatment 123:1, 133-138
CrossRef72
Brian T. Helfand, Angela J. Fought, Stacy Loeb, Joshua J. Meeks, Donghui Kan, William J. Catalona. (2010) Genetic Prostate Cancer Risk Assessment: Common Variants in 9 Genomic Regions are Associated With Cumulative Risk. The Journal of Urology 184:2, 501-505
CrossRef73
Kathleen Calzone, Daniel Wattendorf, Barbara K. Dunn. (2010) The Application of Genetics and Genomics to Cancer Prevention. Seminars in Oncology 37:4, 407-418
CrossRef74
Feero, W. Gregory, Guttmacher, Alan E., , Manolio, Teri A., . (2010) Genomewide Association Studies and Assessment of the Risk of Disease. New England Journal of Medicine 363:2, 166-176
Full Text75
Kerstin Borgmann, Annette Raabe, Sebastian Reuther, Silke Szymczak, Thorsten Schlomm, Hendrik Isbarn, Maria Gomolka, Andreas Busjahn, Michael Bonin, Andreas Ziegler, Ekkehard Dikomey. (2010) The potential role of G2- but not of G0-radiosensitivity for predisposition of prostate cancer. Radiotherapy and Oncology 96:1, 19-24
CrossRef76
Ingrid Metzler. (2010) Biomarkers and their consequences for the biomedical profession: a social science perspective. Personalized Medicine 7:4, 407-420
CrossRef77
J. P. A. Ioannidis, P. Castaldi, E. Evangelou. (2010) A Compendium of Genome-Wide Associations for Cancer: Critical Synopsis and Reappraisal. JNCI Journal of the National Cancer Institute 102:12, 846-858
CrossRef78
Matthew S. Wosnitzer, Franklin C. Lowe. (2010) Management of prostate cancer in HIV-positive patients. Nature Reviews Urology 7:6, 348-357
CrossRef79
Laurence Klotz. (2010) Active Surveillance for Prostate Cancer: A Review. Current Urology Reports 11:3, 165-171
CrossRef80
Sandra Demaria, Eli Pikarsky, Michael Karin, Lisa M. Coussens, Yen-Ching Chen, Emad M. El-Omar, Giorgio Trinchieri, Steven M. Dubinett, Jenny T. Mao, Eva Szabo, Arthur Krieg, George J. Weiner, Bernard A. Fox, George Coukos, Ena Wang, Robert T. Abraham, Michele Carbone, Michael T. Lotze. (2010) Cancer and Inflammation: Promise for Biologic Therapy. Journal of Immunotherapy 33:4, 335-351
CrossRef81
Timothy J. R. Harris, Frank McCormick. (2010) The molecular pathology of cancer. Nature Reviews Clinical Oncology 7:5, 251-265
CrossRef82
Peter R. EASTWOOD, Atul MALHOTRA, Lyle J. PALMER, Eric J. KEZIRIAN, Richard L. HORNER, Mary S. IP, Robert THURNHEER, Nick A. ANTIC, David R. HILLMAN. (2010) Obstructive Sleep Apnoea: From pathogenesis to treatment: Current controversies and future directions. Respirology 15:4, 587-595
CrossRef83
Seth P. Lerner, H. Barton Grossman, Edward M. Messing, Adam S. Kibel, Andrew Stephenson, Jason R. Gee, Michael A. O'Donnell, Robert D. Reid, Ashish M. Kamat, Howard L. Parnes, Margaret G. House. (2010) BCAN Think Tank session 3: Prevention of bladder cancer. Urologic Oncology: Seminars and Original Investigations 28:3, 338-342
CrossRef84
Margaret A Keller, Erynn S Gordon, Catharine B Stack, Neda Gharani, Courtney J Sill, Tara J Schmidlen, Mintzer Joseph, John Pallies, Norman P Gerry, Michael F Christman. (2010) Coriell Personalized Medicine Collaborative ® : a prospective study of the utility of personalized medicine. Personalized Medicine 7:3, 301-317
CrossRef85
Elizabeth Kathryn Bancroft. (2010) Genetic testing for cancer predisposition and implications for nursing practice: narrative review. Journal of Advanced Nursing 66:4, 710-737
CrossRef86
Chee Seng Ku, En Yun Loy, Yudi Pawitan, Kee Seng Chia. (2010) The pursuit of genome-wide association studies: where are we now?. Journal of Human Genetics 55:4, 195-206
CrossRef87
Ramal Moonesinghe, Tiebin Liu, Muin J Khoury. (2010) Evaluation of the discriminative accuracy of genomic profiling in the prediction of common complex diseases. European Journal of Human Genetics 18:4, 485-489
CrossRef88
Qing Lu, Yuehua Cui, Chengyin Ye, Changshuai Wei, Robert C. Elston. (2010) Bagging Optimal ROC Curve Method for Predictive Genetic Tests, with an Application for Rheumatoid Arthritis. Journal of Biopharmaceutical Statistics 20:2, 401-414
CrossRef89
2010. References. , 451-487.
CrossRef90
Gayathri Sridhar, Saba W. Masho, Tilahun Adera, Viswanathan Ramakrishnan, John D. Roberts. (2010) Association between family history of cancers and risk of prostate cancer. Journal of Men's Health 7:1, 45-54
CrossRef91
Rodolfo Valdez, Paula W. Yoon, Nadeem Qureshi, Ridgely Fisk Green, Muin J. Khoury. (2010) Family History in Public Health Practice: A Genomic Tool for Disease Prevention and Health Promotion *. Annual Review of Public Health 31:1, 69-87
CrossRef92
John S. Witte. (2010) Genome-Wide Association Studies and Beyond. Annual Review of Public Health 31:1, 9-20
CrossRef93
J. Xu, S. L. Zheng, S. D. Isaacs, K. E. Wiley, F. Wiklund, J. Sun, A. K. Kader, G. Li, L. D. Purcell, S.-T. Kim, F.-C. Hsu, P. Stattin, J. Hugosson, J. Adolfsson, P. C. Walsh, J. M. Trent, D. Duggan, J. Carpten, H. Gronberg, W. B. Isaacs. (2010) Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proceedings of the National Academy of Sciences 107:5, 2136-2140
CrossRef94
Andrew J. Stephenson, Robert Abouassaly, Eric A. Klein. (2010) Chemoprevention of Prostate Cancer. Urologic Clinics of North America 37:1, 11-21
CrossRef95
Seong-Tae Kim, Yu Cheng, Fang-Chi Hsu, Tao Jin, A. Karim Kader, S. Lilly Zheng, William B. Isaacs, Jianfeng Xu, Jielin Sun. (2010) Prostate cancer risk-associated variants reported from genome-wide association studies: Meta-analysis and their contribution to genetic Variation. The Prostaten/a-n/a
CrossRef96
Kojiro Yano. (2010) Gene expression correlation analysis predicts involvement of high- and low-confidence risk genes in different stages of prostate carcinogenesis. The Prostaten/a-n/a
CrossRef97
J. Li, R. J. Coates, M. Gwinn, M. J. Khoury. (2010) Steroid 5- -Reductase Type 2 (SRD5a2) Gene Polymorphisms and Risk of Prostate Cancer: A HuGE Review. American Journal of Epidemiology 171:1, 1-13
CrossRef98
Ku Chee-Seng, Loy En Yun, Pawitan Yudi, Chia Kee-Seng. 2009. Genome-wide Association Studies: The Success, Failure and Future. .
CrossRef99
Wei Wang, Takeshi Yuasa, Norihiko Tsuchiya, Zhiyong Ma, Shinya Maita, Shintaro Narita, Teruaki Kumazawa, Takamitsu Inoue, Hiroshi Tsuruta, Yohei Horikawa, Mitsuru Saito, Weilie Hu, Osamu Ogawa, Tomonori Habuchi. (2009) The novel tumor-suppressor Mel-18 in prostate cancer: Its functional polymorphism, expression and clinical significance. International Journal of Cancer 125:12, 2836-2843
CrossRef100
Quanhe Yang, W. Dana Flanders, Ramal Moonesinghe, John P.A. Ioannidis, Idris Guessous, Muin J. Khoury. (2009) Using Lifetime Risk Estimates in Personal Genomic Profiles: Estimation of Uncertainty. The American Journal of Human Genetics 85:6, 786-800
CrossRef101
A. McClure, M. Lunt, S. Eyre, X. Ke, W. Thomson, A. Hinks, J. Bowes, L. Gibbons, D. Plant, A. G. Wilson, I. Marinou, A. W. Morgan, P. Emery, , S. Steer, L. J. Hocking, D. M. Reid, P. Wordsworth, P. Harrison, J. Worthington, A. Barton. (2009) Investigating the viability of genetic screening/testing for RA susceptibility using combinations of five confirmed risk loci. Rheumatology 48:11, 1369-1374
CrossRef102
Monique J. Roobol, Fritz H. Schröder, E. David Crawford, Stephen J. Freedland, A. Oliver Sartor, Neil Fleshner, Gerald L. Andriole. (2009) A Framework for the Identification of Men at Increased Risk for Prostate Cancer. The Journal of Urology 182:5, 2112-2122
CrossRef103
Stacy Loeb, Brian T. Helfand, Donghui Kan, William B. Isaacs, William J. Catalona. (2009) Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness?. BJU International 104:9, 1200-1203
CrossRef104
Julius Gudmundsson, Patrick Sulem, Daniel F Gudbjartsson, Thorarinn Blondal, Arnaldur Gylfason, Bjarni A Agnarsson, Kristrun R Benediktsdottir, Droplaug N Magnusdottir, Gudbjorg Orlygsdottir, Margret Jakobsdottir, Simon N Stacey, Asgeir Sigurdsson, Tiina Wahlfors, Teuvo Tammela, Joan P Breyer, Kate M McReynolds, Kevin M Bradley, Berta Saez, Javier Godino, Sebastian Navarrete, Fernando Fuertes, Laura Murillo, Eduardo Polo, Katja K Aben, Inge M van Oort, Brian K Suarez, Brian T Helfand, Donghui Kan, Carlo Zanon, Michael L Frigge, Kristleifur Kristjansson, Jeffrey R Gulcher, Gudmundur V Einarsson, Eirikur Jonsson, William J Catalona, Jose I Mayordomo, Lambertus A Kiemeney, Jeffrey R Smith, Johanna Schleutker, Rosa B Barkardottir, Augustine Kong, Unnur Thorsteinsdottir, Thorunn Rafnar, Kari Stefansson. (2009) Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nature Genetics 41:10, 1122-1126
CrossRef105
Jianfeng Xu, Jielin Sun, A. Karim Kader, Sara Lindström, Fredrik Wiklund, Fang-Chi Hsu, Jan-Erik Johansson, S. Lilly Zheng, Gilles Thomas, Richard B. Hayes, Peter Kraft, David J. Hunter, Stephen J. Chanock, William B. Isaacs, Henrik Grönberg. (2009) Estimation of absolute risk for prostate cancer using genetic markers and family history. The Prostate 69:14, 1565-1572
CrossRef106
A L Teixeira, R Ribeiro, A Morais, F Lobo, A Fraga, F Pina, F M Calais-da-Silva, F E Calais-da-Silva, R Medeiros. (2009) Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. The Pharmacogenomics Journal 9:5, 341-346
CrossRef107
Prodipto Pal, Huifeng Xi, Saurav Guha, Guangyun Sun, Brian T. Helfand, Joshua J. Meeks, Brian K. Suarez, William J. Catalona, Ranjan Deka. (2009) Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry. The Prostate 69:14, 1548-1556
CrossRef108
H Zhang, J L Bermejo, J Sundquist, K Hemminki. (2009) Prostate cancer as a first and second cancer: effect of family history. British Journal of Cancer 101:6, 935-939
CrossRef109
Noel T. Brewer, Alrick S. Edwards, Suzanne C. O’Neill, Janice P. Tzeng, Lisa A. Carey, Barbara K. Rimer. (2009) When genomic and standard test results diverge: implications for breast cancer patients’ preference for chemotherapy. Breast Cancer Research and Treatment 117:1, 25-29
CrossRef110
Lucinda Hughes, Veda N Giri. (2009) Genetic polymorphisms and early-onset prostate cancer: a real potential to personalize prostate cancer screening?. Future Oncology 5:7, 923-926
CrossRef111
A. Karim Kader, Jielin Sun, Sarah D. Isaacs, Kathleen E. Wiley, Guifang Yan, Seong-Tae Kim, Helen Fedor, Angelo M. DeMarzo, Jonathan I. Epstein, Patrick C. Walsh, Alan W. Partin, Bruce Trock, S. Lilly Zheng, Jianfeng Xu, William Isaacs. (2009) Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. The Prostate 69:11, 1195-1205
CrossRef112
Sari Tuupanen, Mikko Turunen, Rainer Lehtonen, Outi Hallikas, Sakari Vanharanta, Teemu Kivioja, Mikael Björklund, Gonghong Wei, Jian Yan, Iina Niittymäki, Jukka-Pekka Mecklin, Heikki Järvinen, Ari Ristimäki, Mariachiara Di-Bernardo, Phil East, Luis Carvajal-Carmona, Richard S Houlston, Ian Tomlinson, Kimmo Palin, Esko Ukkonen, Auli Karhu, Jussi Taipale, Lauri A Aaltonen. (2009) The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nature Genetics 41:8, 885-890
CrossRef113
Cheng-Hong Yang, Hsueh-Wei Chang, Yu-Huei Cheng, Li-Yeh Chuang. (2009) Novel generating protective single nucleotide polymorphism barcode for breast cancer using particle swarm optimization. Cancer Epidemiology 33:2, 147-154
CrossRef114
Phillip G. Febbo. (2009) Genomic approaches to outcome prediction in prostate cancer. Cancer 115:S13, 3046-3057
CrossRef115
Dimosthenis Ziogas, Dimitrios H. Roukos. (2009) Genetics and Personal Genomics for Personalized Breast Cancer Surgery: Progress and Challenges in Research and Clinical Practice. Annals of Surgical Oncology 16:7, 1771-1782
CrossRef116
Stacy Loeb, H. Ballentine Carter, Patrick C. Walsh, William B. Isaacs, Anna Kettermann, Toshiko Tanaka, Luigi Ferrucci, E. Jeffrey Metter. (2009) Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate Specific Antigen Level. The Journal of Urology 182:1, 101-105
CrossRef117
Spencer K. Watson, Bruce W. Woolcock, John N. Fee, Terry C. Bainbridge, Douglas Webber, Thomas J. Kinahan, Wan L. Lam, Juergen R. Vielkind. (2009) Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization. The Prostate 69:9, 961-975
CrossRef118
Brian T. Helfand, Stacy Loeb, Joshua J. Meeks, Angela J. Fought, Donghui Kan, William J. Catalona. (2009) Pathological Outcomes Associated With the 17q Prostate Cancer Risk Variants. The Journal of Urology 181:6, 2502-2507
CrossRef119
J. Pan, J. Lin, J. G. Izzo, Y. Liu, J. Xing, M. Huang, J. A. Ajani, X. Wu. (2009) Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway. Carcinogenesis 30:5, 785-792
CrossRef120
Yves Fradet. (2009) Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. Current Opinion in Urology 19:3, 243-246
CrossRef121
Julie N Harris, Deborah J Bowen, Alan Kuniyuki, Laura McIntosh, Liesel M Fitzgerald, Elaine A Ostrander, Janet L Stanford. (2009) Interest in genetic testing among affected men from hereditary prostate cancer families and their unaffected male relatives. Genetics in Medicine 11:5, 344-355
CrossRef122
Neil E. Fleshner, Nathan Lawrentschuk. (2009) Risk of Developing Prostate Cancer in the Future: Overview of Prognostic Biomarkers. Urology 73:5, S21-S27
CrossRef123
Gau-Tyan Lin, Hung-Fu Tseng, Cheng-Hong Yang, Ming-Feng Hou, Li-Yeh Chuang, Hsiao-Ting Tai, Ming-Hong Tai, Yu-Huei Cheng, Cheng-Hao Wen, Chih-Shan Liu, Chih-Jen Huang, Chun-Lin Wang, Hsueh-Wei Chang. (2009) Combinational Polymorphisms of Seven CXCL12-Related Genes Are Protective against Breast Cancer in Taiwan. OMICS: A Journal of Integrative Biology 13:2, 165-172
CrossRef124
Peter Kraft, Sholom Wacholder, Marilyn C. Cornelis, Frank B. Hu, Richard B. Hayes, Gilles Thomas, Robert Hoover, David J. Hunter, Stephen Chanock. (2009) Beyond odds ratios — communicating disease risk based on genetic profiles. Nature Reviews Genetics 10:4, 264-269
CrossRef125
Kari Hemminki, Asta Försti, Justo Lorenzo Bermejo. (2009) Surveying the Genomic Landscape of Colorectal Cancer. The American Journal of Gastroenterology 104:3, 789-790
CrossRef126
Fredrik Wiklund, S. Lilly Zheng, Jielin Sun, Hans-Olov Adami, Hans Lilja, Fang-Chi Hsu, Pär Stattin, Jan Adolfsson, Scott D. Cramer, David Duggan, John D. Carpten, Bao-Li Chang, William B. Isaacs, Henrik Grönberg, Jianfeng Xu. (2009) Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. The Prostate 69:4, 419-427
CrossRef127
Claudia A. Salinas, Joseph S. Koopmeiners, Erika M. Kwon, Liesel FitzGerald, Daniel W. Lin, Elaine A. Ostrander, Ziding Feng, Janet L. Stanford. (2009) Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. The Prostate 69:4, 363-372
CrossRef128
Yun Suk Huh, Adam J. Lowe, Aaron D. Strickland, Carl A. Batt, David Erickson. (2009) Surface-Enhanced Raman Scattering Based Ligase Detection Reaction. Journal of the American Chemical Society 131:6, 2208-2213
CrossRef129
Kazutoshi Fujita, Charles M. Ewing, David Y.S. Chan, Leslie A. Mangold, Alan W. Partin, William B. Isaacs, Christian P. Pavlovich. (2009) Endoglin (CD105) as a urinary and serum marker of prostate cancer. International Journal of Cancer 124:3, 664-669
CrossRef130
John S. Witte. (2009) Prostate cancer genomics: towards a new understanding. Nature Reviews Genetics 10:2, 77-82
CrossRef131
Amit R Patel, Eric A Klein. (2009) Risk factors for prostate cancer. Nature Clinical Practice Urology 6:2, 87-95
CrossRef132
Christopher P. Evans. (2009) Identification of molecular targets in urologic oncology. World Journal of Urology 27:1, 3-8
CrossRef133
B.-L. Chang, S. D. Cramer, F. Wiklund, S. D. Isaacs, V. L. Stevens, J. Sun, S. Smith, K. Pruett, L. M. Romero, K. E. Wiley, S.-T. Kim, Y. Zhu, Z. Zhang, F.-C. Hsu, A. R. Turner, J. Adolfsson, W. Liu, J. W. Kim, D. Duggan, J. Carpten, S. L. Zheng, C. Rodriguez, W. B. Isaacs, H. Gronberg, J. Xu. (2009) Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Human Molecular Genetics 18:7, 1368-1375
CrossRef134
Dimitrios H Roukos. (2009) Assessing both genetic variation (SNPs/CNVs) and gene–environment interactions may lead to personalized gastric cancer prevention. Expert Review of Molecular Diagnostics 9:1, 1-6
CrossRef135
Coral E. Gartner, Jan J. Barendregt, Wayne D. Hall. (2009) Multiple genetic tests for susceptibility to smoking do not outperform simple family history. Addiction 104:1, 118-126
CrossRef136
Jessica Lubahn, Sonja I. Berndt, Carol H. Jin, Aleksandra Klim, Jason Luly, William S. Wu, Sarah Isaacs, Kathleen Wiley, William B. Isaacs, Brian K. Suarez, Richard B. Hayes, Adam S. Kibel. (2009) Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. The Prostaten/a-n/a
CrossRef137
Stanley Hooker, Wenndy Hernandez, Hankui Chen, Christiane Robbins, Jada Benn Torres, Chiledum Ahaghotu, John Carpten, Rick A. Kittles. (2009) Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans. The Prostaten/a-n/a
CrossRef138
S. Joseph Sirintrapun, Anil V. Parwani. (2008) Molecular Pathology of the Genitourinary Tract: Prostate and Bladder. Surgical Pathology Clinics 1:1, 211-236
CrossRef139
Rona J Strawbridge, Monica Nister, Kerstin Brismar, Chunde Li, Sara Lindström. (2008) Influence of MUC1 genetic variation on prostate cancer risk and survival. European Journal of Human Genetics 16:12, 1521-1525
CrossRef140
Stacy Loeb. (2008) Does PCA3 Help Identify Clinically Significant Prostate Cancer?. European Urology 54:5, 980-981
CrossRef141
Xifeng Wu, Charles Lu, Yuanqing Ye, Joe Chang, Hushan Yang, Jie Lin, Jian Gu, Waun Ki Hong, David Stewart, Margaret R. Spitz. (2008) Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenetics and Genomics 18:11, 955-965
CrossRef142
Bora Gurel, Tsuyoshi Iwata, Cheryl M. Koh, Srinivasan Yegnasubramanian, William G. Nelson, Angelo M. De Marzo. (2008) Molecular Alterations in Prostate Cancer as Diagnostic, Prognostic, and Therapeutic Targets. Advances in Anatomic Pathology 15:6, 319-331
CrossRef143
Sharon A Savage. (2008) Cancer genetic association studies in the genome-wide age. Personalized Medicine 5:6, 589-597
CrossRef144
D. F. Easton, R. A. Eeles. (2008) Genome-wide association studies in cancer. Human Molecular Genetics 17:R2, R109-R115
CrossRef145
A. C. J.W. Janssens, C. M. van Duijn. (2008) Genome-based prediction of common diseases: advances and prospects. Human Molecular Genetics 17:R2, R166-R173
CrossRef146
Jielin Sun, Siqun Lilly Zheng, Fredrik Wiklund, Sarah D Isaacs, Lina D Purcell, Zhengrong Gao, Fang-Chi Hsu, Seong-Tae Kim, Wennuan Liu, Yi Zhu, Pär Stattin, Hans-Olov Adami, Kathleen E Wiley, Latchezar Dimitrov, Jishan Sun, Tao Li, Aubrey R Turner, Tamara S Adams, Jan Adolfsson, Jan-Erik Johansson, James Lowey, Bruce J Trock, Alan W Partin, Patrick C Walsh, Jeffrey M Trent, David Duggan, John Carpten, Bao-Li Chang, Henrik Grönberg, William B Isaacs, Jianfeng Xu. (2008) Evidence for two independent prostate cancer risk–associated loci in the HNF1B gene at 17q12. Nature Genetics 40:10, 1153-1155
CrossRef147
Genevive Bjorn. (2008) Barriers set up to protect genome databases. Nature Medicine 14:10, 996-996
CrossRef148
Dimitrios H Roukos. (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Review of Molecular Diagnostics 8:5, 587-597
CrossRef149
Jielin Sun, Bao-Li Chang, Sarah D. Isaacs, Kathleen E. Wiley, Fredrik Wiklund, Pär Stattin, David Duggan, John D. Carpten, Bruce J. Trock, Alan W. Partin, Patrick C. Walsh, Henrik Grönberg, Jianfeng Xu, William B. Isaacs, S. Lilly Zheng. (2008) Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. The Prostate 68:12, 1257-1262
CrossRef150
Ralph Snyderman, Ziggy Yoediono. (2008) Perspective: Prospective Health Care and the Role of Academic Medicine: Lead, Follow, or Get Out of the Way. Academic Medicine 83:8, 707-714
CrossRef151
M. H. Gail. (2008) Discriminatory Accuracy From Single-Nucleotide Polymorphisms in Models to Predict Breast Cancer Risk. JNCI Journal of the National Cancer Institute 100:14, 1037-1041
CrossRef152
(2008) Cholesterol Gene Polymorphisms and Cardiovascular Events. New England Journal of Medicine 359:1, 92-93
Full Text153
Giorgio Sirugo, Branwen J. Hennig, Adebowale A. Adeyemo, Alice Matimba, Melanie J. Newport, Muntaser E. Ibrahim, Kelli K. Ryckman, Alessandra Tacconelli, Renato Mariani-Costantini, Giuseppe Novelli, Himla Soodyall, Charles N. Rotimi, Raj S. Ramesar, Sarah A. Tishkoff, Scott M. Williams. (2008) Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics. Human Genetics 123:6, 557-598
CrossRef154
Sarah S. Murray, Eric J. Topol. (2008) Gaining Insights in Coronary Disease Genomics
Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 52:5, 385-386
CrossRef155
Robert Getzenberg. (2008) WHAT IS THE FUTURE OF PROSTATE-SPECIFIC ANTIGEN FOR THE EARLY DETECTION OF PROSTATE CANCER?. BJU International 102:2, 157-158
CrossRef156
David P. Wood. (2008) Editorial Comment. The Journal of Urology 180:1, 46
CrossRef157
(2008) Five Genetic Variants Associated with Prostate Cancer. New England Journal of Medicine 358:25, 2738-2741
Full Text158
Peter Albertsen. (2008) Should patients consider active surveillance?. Cancer 112:12, 2631-2634
CrossRef159
Lisa W Chu, Juergen KV Reichardt, Ann W Hsing. (2008) Androgens and the molecular epidemiology of prostate cancer. Current Opinion in Endocrinology, Diabetes and Obesity 15:3, 261-270
CrossRef160
Christopher P. Evans. (2008) Editorial Comment. The Journal of Urology 179:6, 2202
CrossRef161
Mark I. McCarthy, Gonçalo R. Abecasis, Lon R. Cardon, David B. Goldstein, Julian Little, John P. A. Ioannidis, Joel N. Hirschhorn. (2008) Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nature Reviews Genetics 9:5, 356-369
CrossRef162
Gelmann, Edward P., . (2008) Complexities of Prostate-Cancer Risk. New England Journal of Medicine 358:9, 961-963
Full Text
- Letters
